This project deals with seven important areas of allogeneic bone marrow transplantation for hematologic malignancy: 1. We propose to conduct a prospective collaborative trial comparing high dose chemoradiotherapy and marrow transplantation to chemotherapy for patients with acute lymphoblastic leukemia during first complete remission. 2. We will perform a phase II study to decrease the relapse rate in patients with leukemia by the addition of cyclophosphamide to the combination of FTBI and VP-16 (acute non-lymphoblastic leukemia (ANLL) in first complete remission, chronic myelogenous leukemia (CML) in chronic phase, acute lymphoblastic leukemia (ALL) and acute non-lymphocyte leukemia not in first remission, chronic myelogenous leukemia not in chronic phase). 3. We will explore the effectiveness of a new preparatory regimen of FTBI, VP-16 and cyclophosphamide in patients receiving matched unrelated transplants or partially matched related transplants. 4. We will also study methods of preventing cytomegalovirus pneumonia by altering the natural history of HCMV infection after allogeneic bone marrow transplantation. 5. We will determine the effectiveness of a new anti-graft-versus-host disease regimen of cyclosporin, prednisone and xomazyme in patients receiving bone marrow allografts from partially matched unrelated or related donors. 6. We will determine the role of thalidomide in the prevention of chronic graft-versus-host disease after allogeneic bone marrow transplantation. 7. We will conduct a randomized trial to determine the efficacy of methotrexate, cyclosporin and prednisone compared to xomazyme, cyclosporin and prednisone for patients receiving matched sibling allografts.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
2P01CA030206-10
Application #
3806744
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
10
Fiscal Year
1991
Total Cost
Indirect Cost
Name
City of Hope National Medical Center
Department
Type
DUNS #
City
Duarte
State
CA
Country
United States
Zip Code
91010
Limaye, Ajit P; La Rosa, Corinna; Longmate, Jeff et al. (2016) Plasma IL-10 Levels to Guide Antiviral Prophylaxis Prevention of Late-Onset Cytomegalovirus Disease, in High Risk Solid Kidney and Liver Transplant Recipients. Transplantation 100:210-6
Jonnalagadda, Mahesh; Mardiros, Armen; Urak, Ryan et al. (2015) Chimeric antigen receptors with mutated IgG4 Fc spacer avoid fc receptor binding and improve T cell persistence and antitumor efficacy. Mol Ther 23:757-68
Wang, Xiuli; Wong, ChingLam W; Urak, Ryan et al. (2015) CMVpp65 Vaccine Enhances the Antitumor Efficacy of Adoptively Transferred CD19-Redirected CMV-Specific T Cells. Clin Cancer Res 21:2993-3002
Mardiros, Armen; Forman, Stephen J; Budde, Lihua E (2015) T cells expressing CD123 chimeric antigen receptors for treatment of acute myeloid leukemia. Curr Opin Hematol 22:484-8
Caruso, Hillary G; Hurton, Lenka V; Najjar, Amer et al. (2015) Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity. Cancer Res 75:3505-18
Israyelyan, A; Goldstein, L; Tsai, W et al. (2015) Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantation. Bone Marrow Transplant 50:26-33
Wussow, Felix; Chiuppesi, Flavia; Martinez, Joy et al. (2014) Human cytomegalovirus vaccine based on the envelope gH/gL pentamer complex. PLoS Pathog 10:e1004524
Rushworth, David; Jena, Bipulendu; Olivares, Simon et al. (2014) Universal artificial antigen presenting cells to selectively propagate T cells expressing chimeric antigen receptor independent of specificity. J Immunother 37:204-13
Jena, Bipulendu; Moyes, Judy S; Huls, Helen et al. (2014) Driving CAR-based T-cell therapy to success. Curr Hematol Malig Rep 9:50-6
Singh, Harjeet; Huls, Helen; Kebriaei, Partow et al. (2014) A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev 257:181-90

Showing the most recent 10 out of 364 publications